Finafloxacin for the treatment of urinary tract infections

Expert Opinion on Investigational Drugs
R BartolettiTruls E Bjerklund Johansen

Abstract

In the past decade, the indiscriminate use of fluoroquinolones in the prophylaxis and treatment of urinary tract infections (UTIs) has led to an increase of antibiotic resistance patterns. Finafloxacin is a new generation fluoroquinolone with interesting preclinical characteristics and pH-related efficacy. This review summarizes finafloxacin's safety profile and prospectively evaluates its specific use in the treatment of UTIs. This article was based on a Medline English literature search. In vitro and in vivo studies have shown that finafloxacin expresses its full antibacterial activity in acidic environments and is able to exert significant bactericidal effects in difficult-to-treat infections. Finafloxacin has a broad antibacterial spectrum and efficient pharmacokinetic absorption. Moreover, it undergoes extensive tissue distribution, resulting in good antibacterial activity for daily dosages from 400 to 800 mg. This novel compound has also been successfully tested on biofilm-related Escherichia coli. Finafloxacin has demonstrated a good safety and tolerability profile in humans when administered orally or intravenously and is thus an interesting compound for the treatment of UTIs. However, further prospective randomized cli...Continue Reading

References

Jan 1, 1976·The Journal of Infectious Diseases·J N MinuthS B Thorsteinsson
Sep 1, 1992·Antimicrobial Agents and Chemotherapy·D M Livermore, J E Corkill
Dec 1, 1983·The Journal of Antimicrobial Chemotherapy·M PapapetropoulouN J Legakis
Feb 24, 2001·International Journal of Antimicrobial Agents·P C Appelbaum, P A Hunter
Aug 29, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·L R Peterson
Mar 12, 2005·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·F Van BambekePaul M Tulkens
Apr 15, 2008·The Journal of Antimicrobial Chemotherapy·Karin Tegmark WisellChristian G Giske
Jun 29, 2011·Antimicrobial Agents and Chemotherapy·Heena PatelH Labischinski
Sep 29, 2011·The Journal of Antimicrobial Chemotherapy·Evgeny A IdelevichKarsten Becker
Oct 1, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·D SteenselsJ Verhaegen
Mar 15, 2013·The Journal of Antimicrobial Chemotherapy·Laetitia G GarciaFrançoise Van Bambeke
Jun 12, 2013·European Urology·Florian M E WagenlehnerTruls E Bjerklund-Johansen

Citations

Mar 5, 2016·Expert Opinion on Investigational Drugs·Martino Maria Zacchè, Ilias Giarenis
Mar 4, 2017·Expert Opinion on Emerging Drugs·Aneela MajeedMayar Mohajer
Aug 9, 2017·Antimicrobial Agents and Chemotherapy·Max TaubertUwe Fuhr

Related Concepts

Antibiotics
Environment
Escherichia coli
Literature
Drug Kinetics
Urinary Tract Infection
Prophylactic Treatment
Clinical Trials, Randomized
Anti-Bacterial Agents
Intravenous

Related Feeds

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.